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Abstract
Background: Autosomal dominant pseudohypoaldosteronism type 1 (PHA1) is a rare inherited
condition that is characterized by renal resistance to aldosterone as well as salt wasting,
hyperkalemia, and metabolic acidosis. Renal PHA1 is caused by mutations of the human
mineralcorticoid receptor gene (MR), but it is a matter of debate whether MR mutations cause
mineralcorticoid resistance via haploinsufficiency or dominant negative mechanism. It was
previously reported that in a case with nonsense mutation the mutant mRNA was absent in
lymphocytes because of nonsense mediated mRNA decay (NMD) and therefore postulated that
haploinsufficiency alone can give rise to the PHA1 phenotype in patients with truncated mutations.
Methods and Results: We conducted genomic DNA analysis and mRNA analysis for familial
PHA1 patients extracted from lymphocytes and urinary sediments and could detect one novel
splice site mutation which leads to exon skipping and frame shift result in premature termination
at the transcript level. The mRNA analysis showed evidence of wild type and exon-skipped RT-PCR
products.
Conclusion: mRNA analysis have been rarely conducted for PHA1 because kidney tissues are
unavailable for this disease. However, we conducted RT-PCR analysis using mRNA extracted from
urinary sediments. We could demonstrate that NMD does not fully function in kidney cells and that
haploinsufficiency due to NMD with premature termination is not sufficient to give rise to the
PHA1 phenotype at least in this mutation of our patient. Additional studies including mRNA analysis
will be needed to identify the exact mechanism of the phenotype of PHA.
Background
Pseudohypoaldosteronism type 1 (PHA1) is a rare inher-
ited condition that is characterized by renal insensitivity
to the action of mineralcorticoids (aldosterone) [1]. At
least two forms of PHA1, autosomal dominant and reces-
sive of the disease have been described. However, patients
with autosomal dominant PHA1 generally have much
milder symptoms of having renal PHA than those with
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autosomal recessive PHA1 which shows multiple target
organ unresponsiveness to mineralcorticoids such as
sweat and salivary glands, colon and kidney [2]. Aldoster-
one plays a crucial role in the regulation of blood pressure
and potassium homeostasis. It binds to the mineralcorti-
coid receptor (MR) in the distal nephron which triggers
increased sodium reabsorption via the epithelial sodium
channel (ENaC) to restore intravascular volume. Recently,
it became clear that mutations in the MR gene (MR or
NR3C2) leads to autosomal dominant renal PHA1 and
mutations in the ENaC alpha, beta and gamma subunit
genes (SCNN1A, SCNN1B and SCNN1G) leads to auto-
somal recessive severe systemic PHA1 [3,4].
Patients with autosomal dominant renal PHA1 generally
require oral salt supplementation, but typically show a
gradual clinical improvement in renal salt loss during
childhood. Some individuals are clinically asymptomatic
but may have elevated PRA and aldosterone levels [2]. In
most cases, renal PHA1 is the result of mutations of the
gene MR, which consists of 10 exons [5]. The MR gene
contains an amino-terminal region that harbors a ligand-
independent transactivation function coded by exon 2
and a conserved DNA binding domain encoded by exon
3-4 and a ligand binding domain responsible for ligand
binding and ligand-dependent transactivation encoded
by exons 5-9 [6]. To date more than 50 different PHA1-
causing mutations in the MR gene have been identified,
including nonsense, frameshift, missense, and splice site
mutations distributed throughout the gene [7-15].
This report concerns a patient with PHA1 with a novel
splice acceptor site mutation which leads to exon skipping
and frame shift result in premature termination at the
transcript level. The mRNA from peripheral blood lym-
phocytes and urinary sediments showed evidence of wild
type and exon-skipped RT-PCR products.
Methods
Case report
The female index patient was born prematurely after 34
weeks of gestation by cesarean section necessitated by pre-
mature membrane rupture. At birth she weighed 1965 g
and presented with respiratory distress because of tran-
sient tachypnea of the newborn. Initial laboratory exami-
nations showed hyponatremia (127 mmol/L),
hyperkalemia (6.5 mmol/L), and extremely elevated
plasma rennin activity (PRA) (>20 ng/ml/hr; normal: <5.4
ng/ml/hr), and plasma aldosterone concentration
(16,000.0 pg/ml; normal: <240 pg/ml) were noted. 17-
OHprogesterone, adrenocorticotropic hormone (ACTH)
and cortisol levels were normal. After her respiratory dis-
tress had improved, the patient showed failure to thrive
and a persistently low serum sodium level. The clinical
and laboratory findings led us to suspect PHA1. At 13 days
of age, a very low salt supplement (0.5 g/day) was started,
after which the electrolyte disturbance was resolved
accompanied by gradual clinical improvement with a nor-
mal growth rate so that sodium supplementation could be
discontinued at 7 months. The patient is currently 8
months old and in good condition, but aldosterone levels
have remained elevated. Her parents were without any
clinical symptoms. Her mother showed normal plasma
electrolytes concentration, but elevated PRA (7.5 ng/ml/
hr) and aldosterone level (931 pg/ml) were noted.
This study was approved by the Institutional Review
Board of Kobe University Graduate School of Medicine
and written informed consent for this study was obtained
from the patient's parents.
Genomic DNA analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes of the patient and her parents as well as of normal
control subjects with the Qiagen kit (Qiagen Inc., Chats-
worth, CA, USA), according to the manufacturer's instruc-
tions. Eleven pairs of oligonucleotide primers were
generated to amplify all eight coding exons of the MR
gene. Polymerase chain reaction (PCR) was performed
and the PCR products were purified with a DNA purifica-
tion kit (Qiagen Japan, Tokyo, Japan), and then analyzed,
including every exon and intron-exon boundary, by direct
sequencing with a DNA sequencer (Perkin-Elmer-ABI,
Foster City, CA, USA).
RNA expression analysis
Total RNA was extracted from peripheral blood leukocytes
of the patient and her mother and from urine sediments
of the mother. The urine sediments were obtained by cen-
trifugation at 1500 rpm for 10 min from 100 mL of early
morning urine. Microscopic examination of these sedi-
ments confirmed that they contained sufficient renal
tubular epithelial cells.
RNA was isolated with the aid of Isogen Kit (Nippon Gene
Co., Toyama, Japan), and was then reverse transcribed
onto cDNA by using random hexamers and the Super-
script III kit (Invitrogen). cDNA was amplified by means
of nested PCR with forward primers located in exon 5 or
6, and the reverse primer complementary to exon 8 or 9
(exon 5, forward: TTGCCTCTTGGGACCAAAT; exon 6,
forward: TCCTTGAAAACATTGAACCTGA; exon 8, reverse:
CCCAGAATTGTTGGGACACT; exon 9 reverse: ATTCCAG-
CAGGTCGCTCAC). After 35 cycles of amplification, PCR
products were separated on 2% agarose and sequenced
with a DNA sequencer (Perkin-Elmer-ABI, Foster City, CA,
USA). Normal control kidney cDNA was obtained from
the Human Kidney cDNA Library (Invitrogen).BMC Nephrology 2009, 10:37 http://www.biomedcentral.com/1471-2369/10/37
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Results
Direct sequencing of the PCR-amplified products dis-
closed one abnormality, namely double peaks of a and c,
signaling a heterozygous a to c substitution at position -2
bp of the acceptor splice site of intron 6, c.2511-2A>C
(Figure 1). This mutation was also found in her mother. It
was therefore hypothesized that exon 7 might have been
skipped in the transcript. To confirm the inactivation of
the splice-acceptor site, mRNA extracted from peripheral
blood leukocytes and urine samples were used to amplify
a fragment of exons 6 to 8 by means of RT-PCR using a
pair of primers recognizing exon 6 and 8. PCR products
from the patient's and her mother's blood samples
showed two bands, one the same size as the control and
the other shorter (Figure 2a). Sequencing of the larger
product showed a normal sequence, but sequencing of the
shorter product indicated complete absence of the exon 7
sequences, that is, exon 6 was directly joined to exon 8
(Figure 2b). Exon 7 of the MR gene contains 131 bp so
that skipping of this exon creates an out-of-frame muta-
tion in mRNA, which in turn introduces a premature stop
codon in exon 8. The PCR products from the mother's
urine sediments also showed two bands, one the same
size as the control and the other shorter, and sequencing
yielded the same result as for the patient's and her
mother's blood samples.
Discussion
In this study we identified a novel mutation c.2511-2A>C
in intron 6 in the MR gene and this mutation was strongly
suspected of eliminating a consensus splice acceptor site,
resulting in exon 7 skipping in the mRNA. Although no
clear evidence has been shown, it is believed that this
mutation in the MR  gene reduces the ligand-binding
capacity of MR [6]. This same mutation was found in the
patient's mother.
Both mother and daughter had a very mild phenotype in
comparison with typical patients with PHA1. For this rea-
son, our patient needed only a small amount of sodium
replacement (0.5 g/day) and this supplement could be ter-
minated early, at the age of 7 months. Her mother was
clinically free of symptoms, had normal plasma electro-
lytes, and showed only elevated PRA and aldosterone
level. No occasion of salt loss, not even during infancy or
childhood, was recorded, and she had never undergone
treatment as an inpatient. Viemann at al reported that the
patients with typical PHA1 need a much larger amount of
salt replacement than did our patient, 4 g/day to 12 g/day
for therapy [7], and it is reported the patients needed the
supplement for a relatively longer time, 1 to 3 years [16].
However, the finding that some patients carrying the MR
mutation have no symptomatic or very mild symptomatic
manifestations can be found in some reports of PHA1
[7,17]. Moreover, distinct differences of the disease sever-
ity between various affected members within one family
or between unrelated individuals carrying the same muta-
tion could be observed [7,14]. We should consider that
salt intake in the diet may modulate the phenotype and
that some patients may compensate their phenotype with-
out treatment just by a high salt diet. However, there is
another possibility that the phenotype of PHA1 may not
originate from the genotype of only the MR mutation. As
postulated by Geller [5] and Tajima [8], it is possible that
either mutations in additional genes or non-genetic fac-
tors may contribute to the clinical and biochemical phe-
notypes of the carriers of MR mutations. However, several
attempts to pin down these additional genes or factors
have been without success [17,18].
About genotype-phenotype correlations, Riepe describes
in his recent review article that no association could be
drawn from the available clinical data and MR gene muta-
tions [19]. This fact may also suggest the existence of other
factors.
Many human diseases that are caused by loss-of-function
mutations in nuclear receptors have been reported, but
the mechanism of the disease differs for each receptor.
Moreover, whether MR mutations cause mineralcorticoid
resistance via haploinsufficiency or dominant negative
mechanism remains controversial. To test the pathogenic
mechanism, Sartorato et al showed in co-transfection
experiments that the two mutated receptors they identi-
fied, Q776R and L979P, exerted a dominant negative
effect on the wild type receptors, and stated that this dom-
inant negative effect is necessary to give rise to autosomal
dominant PHA1 [7]. However, Riepe et al and Balsamo et
al performed the same co-transfection experiments and
Nucleotide change Figure 1
Nucleotide change. The nucleotide change identified in the 
pseudohypoaldosteronism type 1 (PHA1) patient by direct 
sequencing analysis. A heterozygous transition (a>c) at posi-
tion -2 bp of the acceptor splice site of intron 6 led to the 
hypothesis that exon 7 might have been skipped in the tran-
script.
Exon 7 
c.2511-2A>C  
TTTCTTCTTTTCCTTTGC  GAGAGAAGATGCAT  C 
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showed that the mutated receptors they identified, C818L,
A1012X, Y134X and L772X, exhibited no dominant nega-
tive effect on the wild-type MR proteins. Therefore, Riepe
et al and Balsamo et al claimed that haploinsufficiency of
the  MR  locus is sufficient to generate PHA1 in their
patients [16,17].
Geller et al had access to RNA analysis to test for non-
sense-mediated mRNA decay (NMD) in a patient with a
nonsense mutation. They found wild type but not mutant
MR mRNA in peripheral blood lymphocytes of a PHA1
patient with a nonsense mutation in exon 3 (A590X). The
absence of a mutant RNA was probably due to NMD, indi-
cating the patient possessed the onset mechanism of hap-
loinsufficiency because there was no mutant mRNA due
to NMD [20].
With genetic analysis using RT-PCR, the problem is some-
times encountered that NMD interferes with the detection
of nonsense mutations. The NMD pathway is an mRNA
surveillance system that typically degrades transcripts con-
taining premature termination codons (PTCs) to prevent
translation of unnecessary or aberrant transcripts. Failure
to eliminate these mRNAs with PTCs may result in the
synthesis of abnormal proteins that can be toxic to cells
through dominant negative or gain-of-function effects.
Geller et al suggested that haploinsufficiency is sufficient
to generate the PHA1 phenotype because of this mecha-
nism [14]. However, we confirmed by means of RT-PCR
that transcripts with exon 7 skipped remain in mRNA
from not only peripheral blood lymphocytes but also uri-
nary sediments. Exon 7 of the MR gene contains 131 bp
and this exon skipping creates an out-of-frame mutation
and leads to PTC in exon 8 in mRNA. However, we could
identify mutant RT-PCR products in our patient, which
means NMD does not always affect mutations with PTCs.
On the other hand, it is possible that the pathogenic
mechanism of PHA1 in patients with MR  mutations
depends on the mutation position. PHA1 is such a rare
inherited disease that only about 40 mutations have been
described by now, so that mRNA analytical studies of this
disease are quite rare and additional studies are necessary
to identify the mechanism of the phenotype of PHA1. It
should be noted that the molar abundance of the smaller
mRNA appears to be lower than the wild type transcript,
that is possibly indicating that there is incomplete NMD
of the mutant transcript in our study. Moreover, this study
includes two limitations. First, we have not conducted
quantitative PCR because we could not amplify clear PCR
products with the one-step PCR, therefore, conducted
nested PCR. Second, we have not determined the mutant
peptide expression analysis because kidney tissues were
unavailable in this disease. We must also hypothesize
that, although not mediated by NMD, haploinsufficiency
given to the loss of major functional domains of the recep-
tor, may be the pathogenic mechanism of PHA1 in this
Electrophoresis of cDNA and a fragment of the sequence cDNA from the patient Figure 2
Electrophoresis of cDNA and a fragment of the sequence cDNA from the patient. (A) PCR using the forward 
primer located in exon 6 and the reverse one located in exon 8. Control samples (a: extracted from leukocytes; b: extracted 
from kidney library) clearly show a single band. The sample from the patient (c: extracted from leukocytes), and her mother (d: 
extracted from leukocytes; e: extracted from urine sediment) shows two bands, one the same size as the control sample (a and 
b), and the other smaller. (B) Normal product (large band) shows a normal sequence. (C) The smaller product (small band) 
shows exon 6 immediately followed by exon 8, so that exon 7 has been skipped. a: control, leukocytes; b: control, kidney 
library; c: patient, leukocytes; d: mother, leukocytes; e: mother, urine sediment.BMC Nephrology 2009, 10:37 http://www.biomedcentral.com/1471-2369/10/37
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patient. However, we can say, at least, some amount of
mutant transcripts are expressed in the kidney tissues and
the onset mechanism of haploinsufficiency because of
complete NMD was denied in our patient.
By using mRNA extracted from urinary sediments, we
could detect transcript abnormality noninvasively. Igar-
ashi et al. were the first to identify transcript abnormalities
by extracting mRNA from urinary sediment cells of
patients with Dent disease [21]. Following their report,
our group used this method to detect splicing abnormali-
ties in mRNA from kidney cells [22-24]. Since urinary sed-
iments contain cells derived from the kidney, genetic
analysis of those cells constitutes an entirely noninvasive,
simple method for the diagnosis of inherited kidney dis-
eases, which can also be used for diagnosis of all other
inherited kidney diseases including renal tubular disor-
ders and glomerular diseases. Our study is the first to use
this method for PHA1.
Conclusion
Our report describes a novel MR mutation in a patient
with PHA, and this mutation was found to eliminate a
splice acceptor site, which results in exon 7 skipping and
subsequently in premature termination in exon 8. This
was demonstrated in mRNA from both peripheral blood
leukocytes and urine sediments.
Our patient and her mother showed very mild symptoms
in spite of a robust mutation of PHA1, which raises the
possibility that MR mutation may not be involved in the
severity of the symptoms of PHA1.
In this novel mutation, RT-PCR products of mRNA
extracted from peripheral blood lymphocytes and urinary
sediments showed evidence of the presence of wild-type
and mutated abnormal mRNA. In our study we could pro-
vide clear evidence that NMD does not operate in mRNA.
We could thus prove that NMD does not always observed
in patients with MR  mutations with PTCs. Additional
studies including mRNA analysis will be needed to iden-
tify the exact mechanism of the phenotype of PHA.
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